- Global Selloff From Dubai Shows Signs of Winding Down
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Tiger Woods Out of Hospital After Accident
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
- Get Paid Six Figures to Wear a T-Shirt?
- The World's Biggest Debtor Nations
- Five Tips for Buying a Foreclosed Home
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
MOST SHARED
- Tiger Woods Out of Hospital After Accident
- The Good Entrepreneur Winner
- Get Paid Six Figures to Wear a T-Shirt?
- Global Selloff From Dubai Woes Shows Signs of Winding Down
- Halftime Report: Dubai - First Ripple Of Larger Crisis?
- Longer Lines, Fuller Carts This Black Friday
- Dubai Spooks Investors But May Bring Buying Opportunity
- Next Week: Cash In Now Or Wait For A Santa Rally?
Text Size 
The wall between a prestigious medical journal and a major drug company may have been shattered.
 |
Alastair Grant / AP GlaxoSmithKline headquarters in London. |
The scientific journal Nature reported today that a peer-reviewer for The New England Journal of Medicine leaked key study results on GlaxoSmithKline's diabetes drug Avandia to the company weeks before they were published.
Steven Haffner with the University of Texas Health Science Center in San Antonio faxed the study to a Glaxo [GSK
Loading...
()
] employee he had worked with on an earlier Avandia study.
Haffner told Nature, "Why I sent it is a mystery. I don't really understand it. I wasn't feeling well. It was bad judgment. I've got a considerable amount of money. I didn't do it to raise my income or anything like that."
Today, Senator Chuck Grassley, the ranking member of the Senate Finance Committee, sent this letter inquiring about the leak to Glaxo's top U.S. executive.
The study in question--an analysis of many clinical trials--showed that Avandia may increase the risk of heart attacks. UK-based Glaxo's stock plummeted when the results were released May 21.
The Food and Drug Administration put a stiff warning on Avandia's label over the findings.
A Glaxo spokesperson told Nature that the inside knowledge that the company had about the study's pending publication "added an additional sense of urgency" to swiftly get the interim results of a more favorable Glaxo-sponsored study published in NEJM.
Peer-reviewers who break confidentiality rules are typically banned from doing future reviews and writing articles or editorials.
The Glaxo employee who received the fax is the senior director of the company's Metabolism Development Center. A Glaxo spokesperson said Haffner sent the study to the employee to get his take on it, but the company told Haffner it couldn't help him.
The spokesperson says the Glaxo executive "didn't do anything wrong."
Print
Email
- These four sectors will be the next to lead the market.
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- It may be the most unusual guide to business you'll read.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
Data is a real-time snapshot *Data is delayed at least 15 minutes